|Articles|November 15, 2022
Utilizing Automated High-Throughput SEC Native Mass Spectrometry for mAb Screening
Author(s)Agilent Technologies
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Year in Review: How FDA Guidances Defined the 2025 Biopharma Landscape
2
Building Robust Biomanufacturing Networks for the Next Wave of Therapies
3
Top BP Videos of 2025: An Intersection of AI, Innovation, and Compliance
4
Biopharma’s 2025 Transformation: A Recap of Our Top 10 Articles
5